Corporate Profile

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

By leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

A royalty bearing collaboration with AbbVie.

Innovative clinical programs: NATIVE and IMPROVES.

Pre-clinical pipeline in oncology and fibrosis.

State-of-the-art R&D capabilities inherited from Abbott, Solvay, Fournier.

Financial Information

Upcoming Events

Q3 2021 financial information – Revenues and cash

10th November 2021
(after U.S market closure)

2021 annual revenues and cash situation 12/31/2021

14th February 2022
(after U.S market closure)

Euronext Share Information

€11.96 -2.92%

Last update: Oct 20, 2021 at 10:00 CET

Open: €12.32
Previous close: €12.32

Day High: €12.32
Day Low: €11.86


12th October 2021
Fireside chat with Frédéric Cren, Inventiva’s CEO during the H.C. Wainwright 5th Annual NASH Investor Conference


Inventiva was co-founded by Frédéric Cren, Chairman, CEO and Co-Founder and Pierre Broqua, Chief Scientific Officer in Dijon in 2012.

Both have strong expertise within the areas of research, development and strategy and held senior research and executive positions at both Fournier and Solvay prior to founding Inventiva.

Investor Contacts

50 rue de Dijon
21121 Daix, France
Tel: +33 (0)3 80 44 75 00

Patti Bank
Managing Director
ICR Westwicke
D 415-513-1284
San Francisco, CA